← Back
Data updated: Mar 10, 2026
EIRGEN
OncologyMetabolic
EIRGEN is a pharmaceutical company focused on Oncology, Metabolic. Key products include CYCLOPHOSPHAMIDE.
2016
Since
3
Drugs
-
Trials
18
Approved (2yr)
Recent Activity
TEMOZOLOMIDE 2026-01-22
Labeling
TEMOZOLOMIDE 2026-01-22
Labeling
CYCLOPHOSPHAMIDE 2025-07-11
Labeling
TEMOZOLOMIDE 2025-07-01
Labeling
CYCLOPHOSPHAMIDE 2025-03-11
Labeling
CYCLOPHOSPHAMIDE 2024-12-30
Labeling
CYCLOPHOSPHAMIDE 2024-12-26
CYCLOPHOSPHAMIDE 2024-12-19
CYCLOPHOSPHAMIDE 2024-12-03
CYCLOPHOSPHAMIDE 2024-10-29
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Oncology 71%
1 drugs Phase 3: 2 Phase 1: 1
Metabolic 29%
1 drugs
Pipeline Strength Pro
Loading...
Active (3)
Discontinued (0)
Company Info
- First Approval
- 2016-02-10
- Latest
- 2024-12-03
- Applications
- 3